Grace Therapeutics, Inc.: Form 10-K for the period ended Mar 31, 2023
Filed with the SEC on Jun 23, 2023 and accepted by EDGAR at Jun 23, 2023, 07:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-04-01 to 2023-03-31 | $10.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-04-01 to 2023-03-31 | −$52.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2022-04-01 to 2023-03-31 | −$9.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-04-01 to 2023-03-31 | −$42.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-04-01 to 2023-03-31 | −$0.95 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-04-01 to 2023-03-31 | −$0.95 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-04-01 to 2023-03-31 | 44,612,831 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-04-01 to 2023-03-31 | −$15.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-03-31 | $27.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $29.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $79.1m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $3.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $11.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $68.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-029498. Last ingested by Listed: Oct 26, 2026, 18:07 ET. Listed shows no prices and gives no investment advice.